Objectives: To summarize recent data on progestin-only contraception (POC) and the risk of thromboembolic events. Methods: A total of 413 pertinent publications were found after a comprehensive search across four databases. 74 full-text publications were examined after duplicates were eliminated using Rayyan QCRI and relevance was checked; five studies finally satisfied the requirements for inclusion.

Results: We included five studies with a total of 380,134 women on hormonal contraception. Emerging evidence suggests an association between POCs and thromboembolic risk, though this risk is generally lower than that of combined hormonal contraceptives with estrogen. Not all POCs carry the same level of safety; injectables, in particular, may have a higher thromboembolic risk due to higher systemic progestin levels. The safety profile also varies by type and administration method, with levonorgestrel-releasing implants and intrauterine devices showing minimal impact on coagulation, while oral progestin-only pills have variable effects depending on the specific progestin used.